The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia.
The Innovative Medicines Initiative-funded COMBACTE consortium fosters academic-industry partnership in pioneering studies to combat serious bacterial infections. We describe how this partnership is advancing the development of 2 monoclonal antibodies, MEDI4893 and MEDI3902, for the prevention of nosocomial pneumonia.
['François|Bruno|B|', 'Chastre|Jean|J|', 'Eggiman|Philippe|P|', 'Laterre|Pierre-François|PF|', 'Torres|Antoni|A|', 'Sanchez|Miguel|M|', 'Esser|Mark T|MT|', 'Bishop|Brian|B|', 'Bonten|Marc|M|', 'Goosens|Herman|H|', 'Jafri|Hasan S|HS|']
D000900:Anti-Bacterial Agents D000911:Antibodies, Monoclonal D003428:Cross Infection D055808:Drug Discovery D006801:Humans D018410:Pneumonia, Bacterial D053717:Pneumonia, Ventilator-Associated D055818:Public-Private Sector Partnerships D014481:United States
nosocomial pneumonia monoclonal antibody ICU ventilator-associated pneumonia